Drug shows promise when used in combo with cancer vaccines

04/24/2007 | Bloomberg Businessweek

Researchers see hope in Medarex's drug ipilimumab, being developed with Bristol-Myers Squibb, as an effective cancer fighter, but only when used in combination with a cancer vaccine. More than 60 vaccines now are undergoing clinical trials, and none has been proven to shrink tumors on its own, just allowing patients to live longer. Ipilimumab may boost the tumor-killing ability of vaccines.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR